Posted On: 12/14/2016 4:33:54 PM
Post# of 1460
10-K is out. They flatly state: "In Septermber 2016, the Company presented positive preclinical data for ANAVEX 2-73 in Parkinson's disease, which demonstrated significant improvements on all measures: behavioral, histopathological, and neuroinflammatory endpoints."
They also talk about how they intend to try to partner up.
They also talk about how they intend to try to partner up.
(1)
(0)Scroll down for more posts ▼
